Cargando…
Autologous Immune Cell-Based Regenerative Therapies to Treat Vasculogenic Erectile Dysfunction: Is the Immuno-Centric Revolution Ready for the Prime Time?
About 35% of patients affected by erectile dysfunction (ED) do not respond to oral phosphodiesterase-5 inhibitors (PDE5i) and more severe vasculogenic refractory ED affects diabetic patients. Innovative approaches, such as regenerative therapies, including stem cell therapy (SCT) and platelet-rich p...
Autores principales: | Bonanni, Michela, Rehak, Laura, Massaro, Gianluca, Benedetto, Daniela, Matteucci, Andrea, Russo, Giulio, Esperto, Francesco, Federici, Massimo, Mauriello, Alessandro, Sangiorgi, Giuseppe Massimo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138496/ https://www.ncbi.nlm.nih.gov/pubmed/35625828 http://dx.doi.org/10.3390/biomedicines10051091 |
Ejemplares similares
-
Endovascular treatment of vasculogenic erectile dysfunction
por: Kim, Edward D, et al.
Publicado: (2015) -
Regenerative Medicine for Erectile Dysfunction Following Radical Prostatectomy: Are we Ready?
por: Albersen, Maarten, et al.
Publicado: (2016) -
Is Regenerative Medicine Ready for Prime Time in Diabetic Polyneuropathy?
por: Himeno, Tatsuhito, et al.
Publicado: (2018) -
Immunomodulation Therapies for Atherosclerosis: The Past, the Present, and the Future
por: Lecis, Dalgisio, et al.
Publicado: (2023) -
The retinal neurovascular coupling is impaired in men with vasculogenic erectile dysfunction
por: Borrelli, Enrico, et al.
Publicado: (2023)